Otto Visser1, Eva Ardanaz2, Laura Botta3, Milena Sant4, Andrea Tavilla5, Pamela Minicozzi4. 1. Department of Registration, Netherlands Comprehensive Cancer Organization, Utrecht, The Netherlands. Electronic address: o.visser@iknl.nl. 2. Navarre Public Health Institute, Pamplona, Spain; CIBER Epidedemiology and Public Health CIBERESP, Madrid, Spain. 3. Department of Preventive and Predictive Medicine, Evaluative Epidemiology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. 4. Department of Preventive and Predictive Medicine, Analytical Epidemiology and Health Impact Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. 5. Centro Nazionale di Epidemiologia, Sorveglianza e Promozione della Salute, Istituto Superiore di Sanità, Rome, Italy.
Abstract
BACKGROUND: Primary malignant brain tumours are rare but represent a serious health burden due to their poor survival. This manuscript describes the survival of malignant brain tumours in adults diagnosed 2000-2007 in Europe. METHODS: For this study we analysed patients archived in 86 European population-based cancer registries, followed up to 31st December 2008. Only primary malignant neuroepithelial brain tumours (with pathological confirmation) and primary malignant unspecified brain tumours without pathological confirmation were included. We estimated 1-year and 5-year relative survival (RS) weighted by age group and country. We also estimated country-specific and age-specific survival, together with survival differences between time periods (for 1999-2001, 2002-2004 and 2005-2007). RESULTS: Glioblastoma represents 49% of all brain tumours, followed by other/unspecified astrocytoma (18%), oligodendroglioma/oligoastrocytoma (9%), ependymoma (1.5%) and embryonal tumours (1%). Five-year RS was 20% for all tumours combined, but ranged from 58% for ependymoma to only 6% for glioblastoma and sharply decreased with increasing age. Differences between countries were relatively small, but generally RS in Ireland/United Kingdom (UK) and Eastern Europe was below the average. An increase in 1-year RS (up to 10-12%) was noted over time, being largest in Central and Northern Europe in patients between 45 and 74years of age. CONCLUSIONS: Despite an increase in 1-year RS in most European regions, the survival of primary malignant brain tumours is still poor. Disparities between countries were evident, being even larger at the end of the study period than at the beginning, suggesting differences in availability of the latest treatment modalities.
BACKGROUND:Primary malignant brain tumours are rare but represent a serious health burden due to their poor survival. This manuscript describes the survival of malignant brain tumours in adults diagnosed 2000-2007 in Europe. METHODS: For this study we analysed patients archived in 86 European population-based cancer registries, followed up to 31st December 2008. Only primary malignant neuroepithelial brain tumours (with pathological confirmation) and primary malignant unspecifiedbrain tumours without pathological confirmation were included. We estimated 1-year and 5-year relative survival (RS) weighted by age group and country. We also estimated country-specific and age-specific survival, together with survival differences between time periods (for 1999-2001, 2002-2004 and 2005-2007). RESULTS:Glioblastoma represents 49% of all brain tumours, followed by other/unspecifiedastrocytoma (18%), oligodendroglioma/oligoastrocytoma (9%), ependymoma (1.5%) and embryonal tumours (1%). Five-year RS was 20% for all tumours combined, but ranged from 58% for ependymoma to only 6% for glioblastoma and sharply decreased with increasing age. Differences between countries were relatively small, but generally RS in Ireland/United Kingdom (UK) and Eastern Europe was below the average. An increase in 1-year RS (up to 10-12%) was noted over time, being largest in Central and Northern Europe in patients between 45 and 74years of age. CONCLUSIONS: Despite an increase in 1-year RS in most European regions, the survival of primary malignant brain tumours is still poor. Disparities between countries were evident, being even larger at the end of the study period than at the beginning, suggesting differences in availability of the latest treatment modalities.
Authors: M D Chirlaque; D Salmerón; J Galceran; A Ameijide; A Mateos; A Torrella; R Jiménez; N Larrañaga; R Marcos-Gragera; E Ardanaz; M Sant; P Minicozzi; C Navarro; M J Sánchez Journal: Clin Transl Oncol Date: 2017-07-17 Impact factor: 3.405
Authors: Haley Gittleman; Alexander Boscia; Quinn T Ostrom; Gabrielle Truitt; Yi Fritz; Carol Kruchko; Jill S Barnholtz-Sloan Journal: Neuro Oncol Date: 2018-11-09 Impact factor: 12.300
Authors: Fabio Girardi; Brian Rous; Charles A Stiller; Gemma Gatta; Naomi Fersht; Hans H Storm; Jessica R Rodrigues; Christian Herrmann; Rafael Marcos-Gragera; Rafael Peris-Bonet; Mikhail Valkov; Hannah K Weir; Ryan R Woods; Hui You; Patricia A Cueva; Prithwish De; Veronica Di Carlo; Tom Børge Johannesen; Carlos A Lima; Charles F Lynch; Michel P Coleman; Claudia Allemani Journal: Neuro Oncol Date: 2021-10-01 Impact factor: 13.029